Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From inRegen
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2014.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Despite market headwinds, the endovascular treatment of acute ischemic stroke remains a growing and highly under-penetrated market opportunity valued at more than $1 billion worldwide. Although advances in neurothrombectomy devices, access catheters, imaging, and neuroprotective therapies have the potential to help expand the treatable population, positive Level I clinical evidence is needed to drive adoption and market growth.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- ProKidney LP
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.